Buyout (control-heavy) fund research profile
EQT’s India private-equity practice is the continuation of Baring Private Equity Asia’s control-oriented platform, now integrated into EQT’s Asia organization. Jimmy Mahtani chairs India, with the team focused on technology services, healthcare and services businesses.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
EQT (BPEA EQT, India) uses a buyout (control-heavy) approach across IT services, health, tech.
Current evidence
EQT’s current portfolio and BPEA fund pages identify India positions including Atain (formerly IGT Solutions), AIG Hospitals, Straive and Indira IVF. EQT’s 2025 year-end report records Sagility as an active BPEA VIII realization and its public fund page lists BPEA VIII at $11.2 billion; India-only allocation and returns remain not publicly disclosed.
Strategy
Buyout (control-heavy)
Sector focus
IT services, health, tech
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
EQT’s current portfolio and BPEA fund pages identify India positions including Atain (formerly IGT Solutions), AIG Hospitals, Straive and Indira IVF. EQT’s 2025 year-end report records Sagility as an active BPEA VIII realization and its public fund page lists BPEA VIII at $11.2 billion; India-only allocation and returns remain not publicly disclosed.
Investor questions
EQT (BPEA EQT, India) is covered in Rupeia's private equity research universe. The current public record describes the strategy as Buyout (control-heavy), with a sector focus of IT services, health, tech. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to EQT (BPEA EQT, India) in the reviewed public sources: Atain (formerly IGT Solutions), Credila Financial Services, Indira IVF, Sagility, Straive, AIG Hospitals, CitiusTech. It does not represent a complete current portfolio unless the manager has published one.
BPEA Private Equity Fund VIII is listed by EQT at $11.2B and includes India positions such as Atain/IGT Solutions, Credila, Indira IVF and Sagility. EQT’s public materials describe operational and technology-led value creation, but India fund-level returns are not disclosed in the reviewed record. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: BPEA Private Equity Fund VIII is reported by EQT at $11.2B, with India and other Asian investments in the same vehicle. India-only fund size and allocation are not disclosed.. Public terms or access information: Control-heavy buyout strategy in India, with a focus on technology services, healthcare and services. BPEA VIII’s disclosed portfolio includes 17 companies across Asia; India cheque sizes and reserve policy are not stated.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Jimmy Mahtani (India head). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: India-only allocation and fund-level performance remain not publicly disclosed; the record is limited to attributable BPEA/EQT India positions within a regional platform..
2026-01-22: EQT’s current portfolio and BPEA fund pages identify India positions including Atain (formerly IGT Solutions), AIG Hospitals, Straive and Indira IVF. EQT’s 2025 year-end report records Sagility as an active BPEA VIII realization and its public fund page lists BPEA VIII at $11.2 billion; India-only allocation and returns remain not publicly disclosed.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.